What is the business case for an employer offering OncuraKit?

The business case for employer-sponsored OncuraKit is straightforward: late-stage cancer is among the most expensive conditions in employer health plans. The average cancer treatment cost ranges from $150,000 (early-stage breast cancer) to $800,000+ (late-stage pancreatic or lung cancer with multiple rounds of immunotherapy and chemotherapy). One late-stage cancer diagnosis can exceed the annual healthcare spend of 50 typical employees. By investing $995 per employee per year in OncuraKit screening, employers can potentially detect cancers at Stage I — where treatment is simpler, less expensive, and more likely to succeed. A 1% cancer incidence rate in employees over 60 means that for every 100 eligible employees screened, one cancer may be found early, potentially saving hundreds of thousands of dollars in catastrophic treatment costs.